Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (> or equal to 1g/ day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone.